Back to Search
Start Over
Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study
- Source :
- The Indian Journal of Medical Research, Indian Journal of Medical Research, Vol 153, Iss 5, Pp 671-676 (2021)
- Publication Year :
- 2021
- Publisher :
- Wolters Kluwer - Medknow, 2021.
-
Abstract
- Background & objectives: Vaccination against SARS-CoV-2 is a recommendation from the World Health Organization as the foremost preference in the current situation to control the COVID-19 pandemic. BBV152 is one of the approved vaccines against SARS-CoV-2 in India. In this study, we determined SARS-CoV-2–specific antibody levels at day 0 (baseline, before vaccination), day 28 ± 2 post-first dose (month 1) and day 56 ± 2 post-first dose (month 2) of BBV152 whole-virion–inactivated SARS-CoV-2 recipients, and compared the antibody responses of individuals with confirmed pre-vaccination SARS-CoV-2 infection to those individuals without prior evidence of infection. Methods: Blood samples were collected from 114 healthcare professionals and frontline workers who received BBV152 vaccine from February to May & June 2021. Prior infection with SARS-CoV-2 was determined at baseline. Serum samples were used to estimate SARS-CoV-2 nucleoprotein-specific IgG [IgG (N)], spike protein-specific IgG [IgG (S)] and neutralizing antibodies (NAb). Results: Participants with previous SARS-CoV-2 infection after a single vaccine dose elicited IgG (N) and IgG (S) antibody levels along with NAb binding inhibition responses levels were similar to infection-naive vaccinated participants who had taken two doses of vaccine. Interpretation & conclusions: Our preliminary data suggested that a single dose of BBV152-induced humoral immunity in previously infected individuals was equivalent to two doses of the vaccine in infection-naive individuals. However, these findings need to be confirmed with large sized cohort studies.
- Subjects :
- BBV152
COVID-19 Vaccines
IgG
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Pilot Projects
Antibodies, Viral
bbv152 - covid-19 vaccine - igg - neutralizing antibody - sars-cov-2
General Biochemistry, Genetics and Molecular Biology
Pandemic
Medicine
Humans
Neutralizing antibody
Pandemics
biology
business.industry
SARS-CoV-2
neutralizing antibody
COVID-19
General Medicine
Vaccination
Antibody response
Immunology
Humoral immunity
Antibody Formation
biology.protein
Original Article
Antibody
business
COVID-19 vaccine
Cohort study
Subjects
Details
- Language :
- English
- ISSN :
- 09759174 and 09715916
- Volume :
- 153
- Issue :
- 5-6
- Database :
- OpenAIRE
- Journal :
- The Indian Journal of Medical Research
- Accession number :
- edsair.doi.dedup.....61b73a9c1a78e666525672b5aed74c3e